

The HMDS Annual Haematopathology Update Day

Incorporating Novel Diagnostics into Patient Management ... Patient Pathways from Laboratory to Bedside

Wednesday 8th September 2021

VIRTUAL EVENT

Organisers: Dr Ruth de Tute, Professor Roger Owen and Dr Cathy Burton, HMDS Leeds

08.45 *Networking suite open*

09.15 Welcome

Dr Cathy Burton, HMDS

CLL

09.15 Clinical CLL

Professor Peter Hillmen, Leeds

09.35 Ibrutinib and other resistance

Dr Tal Munir, Leeds

09.55 MDR in the era of novel therapies

Dr Andy Rawstron, Leeds

10.15 Panel discussion with speakers and questions from the audience

10.45 *Break and networking*

Myeloma

11.05 Clinical update – update from myeloma trials

Dr Charlotte Pawlyn, London

11.25 Sequential MRD monitoring in myeloma

Dr Ruth de Tute, Leeds

11.45 Cellular therapies in myeloma

Dr Frances Seymour, Leeds

12.15 Panel discussion with speakers and questions from the audience

12.45 *Lunch break, networking, meet the sponsors*

Lymphoma

13.15 Overview and role of bi-specific antibodies

Dr Will Townsend, London

13.40 Molecular analysis and classification of lymphoid
lymphoid malignancies

Dr Sharon Barrans, Leeds

14.00 Molecular subclusters of follicular lymphoma

Professor Reuben Tooze, Leeds

14.20 Panel discussion with speakers and questions from the audience

14.30 *Break and networking*

Myeloid & Genomics

14.45 Using genetics to determine AML therapy

Professor Brian Huntly, Cambridge

15.10 Single high-throughput sequencing panel for use in all
haematological malignancies: Leeds HMDS experience

Dr Paul Evans, Leeds

Continued over page

Rare and Atypical Myeloproliferations

15.30 Eosinophila – an update

Professor Nick Cross, *Salisbury*

15.50 Myeloproliferative neoplasms

Dr Adam Mead, *Oxford*

16.20 Discussion panel with speakers and questions from delegates

16.30 *Summary & Close*

Registration for this meeting is free of charge for HCPs working within the NHS

Register on-line at www.hartleytaylor.co.uk

Enquiries: Please contact alex@hartleytaylor.co.uk



This meeting will be supported by pharmaceutical companies with virtual exhibition stands who have had no input into the programme